Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL728303 | 0.92 | NAAA (0.47) | NAAASMN1; SMN2KMT2AGAAMEN1 | |
| SCHEMBL2734644 | 0.87 | GAA (0.43) | NAAASMN1; SMN2KMT2AGAAMEN1 | |
| SCHEMBL7753713 | 0.85 | NAAA (0.40) | NAAASMN1; SMN2KMT2AGAAMEN1 | |
| SCHEMBL27632925 | 0.83 | NAAA (0.43) | NAAASMN1; SMN2KMT2AGAAMEN1 | |
| SCHEMBL1150064 | 0.81 | CHRM2 (0.34) | NAAAKMT2AGAAMEN1TSHR | |
| SCHEMBL463020 | 0.79 | SMN1; SMN2 (0.47) | NAAASMN1; SMN2KMT2AGAAMEN1 | |
| SCHEMBL6299625 | 0.79 | GAA (0.44) | NAAASMN1; SMN2KMT2AGAAMEN1 | |
| SCHEMBL316372 | 0.79 | SMN1; SMN2 (0.47) | NAAASMN1; SMN2KMT2AGAAMEN1 | |
| SCHEMBL5649676 | 0.79 | SMN1; SMN2 (0.44) | NAAASMN1; SMN2KMT2AGAAMEN1 | |
| SCHEMBL755468 | 0.78 | NAAA (0.47) | NAAASMN1; SMN2KMT2AGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338110-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | WISCONSIN MED COLLEGE INC (US) | 2013-12-19 | — | — | US | disclosed |
| US-8466130-B2 | Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers | COLBY PHARMACEUTICAL COMPANY (US) | 2013-06-18 | — | — | US | disclosed |
| US-20110059922-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | COLBY PHARMACEUTICAL COMPANY (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2139522-A2 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | Colby Pharmaceutical Company (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008109740-A2 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | COLBY PHARMACEUTICAL COMPANY (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338110-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | TFAM, HSPD1, NLN | NAAA 1249/4885SMN1; SMN2 1845/4885KMT2A 3446/4885 |
| US-20110059922-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | TFAM, HSPD1, NLN | NAAA 1249/4885SMN1; SMN2 1845/4885KMT2A 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.